BlossomHill Therapeutics, Inc.
BLSM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001839970
In the last 90 days, BlossomHill Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $15.2M in total
- 5
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding BLSM, Q2 2026
No superinvestor reported holding BLSM at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by BlossomHill Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 (view filing)4:46 PM ET | Aug 10 | 2 days | Gordon Carl LDirector | PPurchase | +625.0K | $16.00 | +$10.0M | +29.9%2.71M after | Duplicate filing |
| Aug 12, 2026 (view filing)4:43 PM ET | Aug 10 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | PPurchase | +625.0K | $16.00 | +$10.0M | +29.9%2.71M after | |
| Aug 10, 2026 (view filing)6:35 PM ET | Aug 10 | Same day | Schmid John P.Director | PPurchase | +6.00K | $16.00 | +$96.0K | New position6.00K after | |
| Aug 10, 2026 (view filing)6:32 PM ET | Aug 10 | Same day | Chen Bihua and 5 othersDirector, 10% Owner | PPurchase | +312.5K | $16.00 | +$5.00M | +9.5%3.61M after | |
| Aug 10, 2026 (view filing)6:27 PM ET | Aug 10 | Same day | Keyes Jason AChief Financial Officer | PPurchase | +700 | $16.00 | +$11.2K | New position700 after | |
| Aug 10, 2026 (view filing)6:26 PM ET | Aug 7-10 | 3 days | Liptak Vincent PaulGeneral Counsel | PPurchase | +4.70K | $15.89 | +$74.7K | +4.4%111.4K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in BlossomHill Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding BLSM in 13F filings for Q2 2026.